Komori
Other Disclosures3750ADR Biomedical Holdings Inc.Electric Appliances & Precision Instruments

Notice Regarding New Orders for Products Related to the High-Concentration Exosome Component-Containing Liquid “NeoCella”

A consolidated subsidiary newly received an order for 11,000 sets of products related to the exosome component-containing liquid “NeoCella” from a general incorporated association operating 12 medical clinics nationwide. Delivery is scheduled for 16 November 2026, and the sales are expected to be recognized in the third quarter of the fiscal year ending March 2027.

Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
11000
Sets
Wording
Conditional
How definitive the wording is.

Announced details

Products related to the high-concentration exosome component-containing liquid “NeoCella (ネオセラ)”
Applicable field (uses covered by this announcement)

Regenerative medicine and medical clinics

Launch date16 November 2026 (scheduled delivery date)
Relationship between the counterparty and the company
ADR Biomedical Holdings Inc.3750
Relationship with the Company

A business relationship in which the Company’s consolidated subsidiary, ADR Therapeutics, supplies and delivers products to the counterparty

CounterpartyGeneral incorporated association (based in Fukuoka Prefecture, operating 12 medical clinics nationwide; name undisclosed)

General incorporated association based in Fukuoka Prefecture and operating 12 medical clinics nationwide

Location (as indicated in this announcement)

Fukuoka Prefecture (the counterparty’s base)

12 medical clinics nationwide
Contract Value

Aggregate sales amount equivalent to 20% of the Company’s sales in the immediately preceding fiscal year, the fiscal year ended March 2026

Impact on Business Performance

The impact on consolidated results for the fiscal year ending March 2027 is currently under review

The company does not address Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredProducts related to the high-concentration exosome component-containing liquid “NeoCella (ネオセラ)”
CounterpartyGeneral incorporated association (based in Fukuoka Prefecture, operating 12 medical clinics nationwide; name undisclosed)
Counterparty overviewGeneral incorporated association based in Fukuoka Prefecture and operating 12 medical clinics nationwide
Relationship with the CompanyA business relationship in which the Company’s consolidated subsidiary, ADR Therapeutics, supplies and delivers products to the counterparty
Contract ValueAggregate sales amount equivalent to 20% of the Company’s sales in the immediately preceding fiscal year, the fiscal year ended March 2026
Launch date16 November 2026 (scheduled delivery date)
Applicable areaRegenerative medicine and medical clinics
LocationFukuoka Prefecture (the counterparty’s base)
Location scale12 medical clinics nationwide
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending March 2027 is currently under review
Items this document does not state (8)
Offering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The disclosure states that ADR Therapeutics has been developing the organizational structure for NeoCella’s research and development and sales operations, and that the products will be supplied and delivered to a general incorporated association operating multiple medical clinics.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding New Orders for Products Related to the High-Concentration Exosome Component-Containing Liquid “NeoCella” | ADR Biomedical Holdings Inc. (3750) timely disclosure | Komori